Clinical Trial Update: Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety and immunogenicity of the dengue vaccine TV005 (TetraVax-DV TV005) in healthy adults, adolescents, and children in Dhaka, Banglad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• TetraVax-DV TV005 (tetravalent dengue virus vaccine TV005)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 2 | Status: COMPLETED | Results posted: 2025-01-17